|
|
Volumn 23, Issue SUPPL. 1, 2011, Pages
|
|
Understanding the value of antiangiogenic therapy in metastatic breast cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE;
BEVACIZUMAB;
CAPECITABINE;
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
PACLITAXEL;
TRASTUZUMAB;
ANTIANGIOGENIC THERAPY;
BREAST CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CANCER SURVIVAL;
DRUG EFFICACY;
EDITORIAL;
HUMAN;
HYPERTENSION;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
DISEASE-FREE SURVIVAL;
FEMALE;
HUMANS;
NEOPLASM METASTASIS;
|
|
EID: 79954987257
PISSN: 10408746
EISSN: None
Source Type: Journal
DOI: 10.1097/01.cco.0000397416.67622.10 Document Type: Editorial |
|
Times cited : (4)
|
|
References (0)
|
